HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk br...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: George Fountzilas, Christos Valavanis, Vassiliki Kotoula, Anastasia G Eleftheraki, Konstantine T. Kalogeras, Olympia Tzaida, Anna Batistatou, Ralf Kronenwett, Ralph M. Wirtz, Mattheos Bobos, Eleni Timotheadou, Nikolaos Soupos, George Pentheroudakis, Helen Gogas, Dimitrios Vlachodimitropoulos, Genovefa Polychronidou, Gerasimos Aravantinos, Angelos Koutras, Christos Christodoulou, Dimitrios Pectasides, P. Arapantoni
Format: Artigo
Sprache:Englisch
Veröffentlicht: 2012
Online-Zugang:https://doi.org/10.1186/1479-5876-10-10
https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-10
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Online

https://doi.org/10.1186/1479-5876-10-10
https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-10

Ähnliche Einträge